Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse. READ MORE
Researchers compared the safety and efficacy of a certain therapy with conventional treatment for patients with relapsed or refractory multiple myeloma.
For patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, dosing zoledronic acid every 12 weeks works as well as the standard dosing interval of every four weeks.
Research in Review
Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma.
A triple-combination treatment strategy is the most effective therapy for patients with relapsed or refractory multiple myeloma, according to a meta-analysis published in the Journal of Clinical Oncology.
The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical trial results.
Researchers conducted an observation chart review of 435 European physicians to analyze the treatment patterns of 7635 patients with multiple myeloma.